A5029635423- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Helicobacter pylori-related gastroenterology studies
- Genomics and Rare Diseases
- Gastrointestinal Tumor Research and Treatment
- Cancer-related gene regulation
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Inflammatory Bowel Disease
- Colorectal Cancer Treatments and Studies
- Lymphoma Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Genomic variations and chromosomal abnormalities
- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Metastasis and carcinoma case studies
- Digestive system and related health
- Renal Diseases and Glomerulopathies
- Esophageal and GI Pathology
- Immune Cell Function and Interaction
- Diverticular Disease and Complications
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Viral-associated cancers and disorders
- Autoimmune and Inflammatory Disorders
- Histiocytic Disorders and Treatments
Universidade do Porto
2014-2025
i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto
2016-2025
Administração Regional de Saúde de Lisboa e Vale do Tejo
2025
Hospital de São João
2016-2024
Hospital Beatriz Ângelo
2023
IPO Porto
2021
Centro Hospitalar do Porto
2018
Istituti di Ricovero e Cura a Carattere Scientifico
2015
University of Genoa
2015
Gastric cancer (GC) represents a global health concern. Despite advances in prevention, diagnosis, and therapy, GC is still the third leading cause of mortality worldwide, with more than 720,000 estimated deaths 2012. Overall survival for advanced disease about 1 year, dismal prognosis that partly due to high levels biological heterogeneity found GC. Indeed, highly heterogeneous from morphological molecular standpoints. The numerous histological classifications currently available reflect...
Proteomics is a powerful approach to study the molecular mechanisms of cancer. In this study, we aim characterize proteomic profile gastric cancer (GC) in patients with diabetes mellitus (DM) type 2. Forty GC tissue samples including 19 cases from diabetic and 21 individuals without (control group) were selected for proteomics analysis. Gastric tissues processed following single-pot, solid-phase-enhanced sample preparation approach—SP3 enzymatic digestion trypsin. The resulting peptides...
Objective To evaluate the risk factors for lymph node metastasis (LNM) after a non-curative (NC) gastric endoscopic submucosal dissection (ESD) and to validate eventually refine eCura scoring system in Western setting. Also, assess rate parietal residual disease. Design Retrospective multicentre multinational study of prospectively collected registries from 19 centres. Patients who had been submitted surgery or at least one follow-up endoscopy were included. The was applied its accuracy...
Abstract Germline CDH1 loss-of-function mutations are causally linked to an increased lifetime risk of diffuse gastric cancer (DGC). Early, multifocal signet ring cell (SRC) lesions ubiquitous among variant carriers, yet only a subset patients will develop advanced DGC. A multi-omics analysis was performed establish the molecular phenotype early SRC and how they differ from DGC using 20 samples human total gastrectomy specimens germline carriers. Spatial transcriptomic demonstrated reduced...
<b>Background and study aims:</b> The HER2 status of small endoscopic biopsies is important for predicting the eligibility patients with metastatic HER2-positive gastric cancer or gastro-esophageal junction (GEJ) anti-HER2 therapy approved by U.S. Food Drug Administration. aim this was to identify minimum biopsy set required evaluate confidence. <b>Patients methods:</b> A total 103 consecutive resected GEJ were retrospectively selected; 2 formalin-fixed, paraffin-embedded samples each...
Background: Epstein-Barr Virus (EBV) positive and microsatellite unstable (MSI-high) gastric cancer (GC) are molecular subgroups with distinctive profiles. We explored the transcriptomic differences between EBV+ MSI-high GCs, expression of current GC immunotherapy targets such as PD-1, PD-L1, CTLA4 Dies1/VISTA. Methods: Using Nanostring Technology comparative bioinformatics, we analyzed 499 genes in 46 classified either EBV (EBER situ hybridization) or (PCR/fragment analysis). PD-L1 protein...